Industry Asks For More Clarity Around Genome Editing Guidance

By Luke Zarzecki / February 12, 2024 at 2:04 PM

New guidance from FDA codifies that genome editing can be approved through the accelerated approval pathway, but Novartis is calling for more consistency and clarity around the standards.


Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.